Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 33 | 2024 | 424 | 4.900 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2013 | 25 | 0.870 |
Why?
|
| Breast Feeding | 3 | 2013 | 47 | 0.850 |
Why?
|
| Humans | 68 | 2024 | 32967 | 0.770 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 115 | 0.750 |
Why?
|
| Female | 49 | 2024 | 20375 | 0.690 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2023 | 47 | 0.690 |
Why?
|
| Accidental Falls | 3 | 2017 | 221 | 0.660 |
Why?
|
| Rural Population | 3 | 2024 | 286 | 0.660 |
Why?
|
| United Nations | 1 | 2020 | 4 | 0.630 |
Why?
|
| Anti-HIV Agents | 5 | 2024 | 61 | 0.630 |
Why?
|
| Statistics as Topic | 1 | 2020 | 104 | 0.620 |
Why?
|
| Electronic Health Records | 3 | 2017 | 182 | 0.610 |
Why?
|
| Male | 42 | 2024 | 19754 | 0.560 |
Why?
|
| Guideline Adherence | 1 | 2018 | 120 | 0.530 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2016 | 9 | 0.510 |
Why?
|
| Pharmacists | 1 | 2016 | 20 | 0.500 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 188 | 0.490 |
Why?
|
| Water Pollutants, Chemical | 1 | 2016 | 4 | 0.490 |
Why?
|
| Fluorocarbons | 1 | 2016 | 21 | 0.490 |
Why?
|
| Family Practice | 1 | 2016 | 49 | 0.490 |
Why?
|
| Internal Medicine | 1 | 2016 | 55 | 0.490 |
Why?
|
| Trauma Centers | 4 | 2017 | 86 | 0.470 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 76 | 0.470 |
Why?
|
| HIV-1 | 2 | 2012 | 46 | 0.460 |
Why?
|
| Adult | 27 | 2024 | 9586 | 0.460 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 388 | 0.450 |
Why?
|
| Simian immunodeficiency virus | 1 | 2015 | 1 | 0.450 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 1 | 0.450 |
Why?
|
| AIDS Vaccines | 1 | 2015 | 2 | 0.450 |
Why?
|
| Hospice Care | 1 | 2015 | 13 | 0.440 |
Why?
|
| Analgesics, Opioid | 4 | 2019 | 252 | 0.440 |
Why?
|
| Advance Care Planning | 1 | 2015 | 15 | 0.440 |
Why?
|
| Terminal Care | 1 | 2015 | 25 | 0.440 |
Why?
|
| Physicians | 1 | 2016 | 165 | 0.430 |
Why?
|
| Primates | 1 | 2015 | 118 | 0.430 |
Why?
|
| Smoking Cessation | 3 | 2021 | 216 | 0.420 |
Why?
|
| Smoking | 4 | 2021 | 531 | 0.420 |
Why?
|
| Chlamydia Infections | 3 | 2022 | 10 | 0.410 |
Why?
|
| Vaginosis, Bacterial | 2 | 2024 | 7 | 0.410 |
Why?
|
| Gonorrhea | 3 | 2022 | 12 | 0.410 |
Why?
|
| Prevalence | 7 | 2022 | 1002 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 541 | 0.380 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 424 | 0.380 |
Why?
|
| Aged | 16 | 2023 | 10637 | 0.370 |
Why?
|
| Middle Aged | 23 | 2024 | 12203 | 0.370 |
Why?
|
| Renal Dialysis | 1 | 2015 | 280 | 0.370 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 754 | 0.360 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2021 | 18 | 0.350 |
Why?
|
| Patient Transfer | 3 | 2016 | 44 | 0.350 |
Why?
|
| United States | 12 | 2023 | 4132 | 0.340 |
Why?
|
| Alabama | 7 | 2023 | 41 | 0.320 |
Why?
|
| Risk Assessment | 6 | 2019 | 1469 | 0.320 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4065 | 0.300 |
Why?
|
| West Virginia | 7 | 2017 | 16 | 0.300 |
Why?
|
| Patient Compliance | 2 | 2022 | 219 | 0.290 |
Why?
|
| Risk Factors | 10 | 2022 | 4001 | 0.290 |
Why?
|
| Computer Simulation | 4 | 2023 | 224 | 0.280 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3708 | 0.280 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 69 | 0.260 |
Why?
|
| Young Adult | 8 | 2024 | 2738 | 0.240 |
Why?
|
| Exercise | 3 | 2023 | 688 | 0.230 |
Why?
|
| Syphilis | 2 | 2022 | 11 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 1477 | 0.230 |
Why?
|
| Trichomonas Infections | 2 | 2021 | 2 | 0.220 |
Why?
|
| Incidence | 4 | 2022 | 1246 | 0.220 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2024 | 1 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 175 | 0.210 |
Why?
|
| Infant, Newborn | 4 | 2016 | 694 | 0.210 |
Why?
|
| Hypertension | 2 | 2022 | 983 | 0.200 |
Why?
|
| Seizures | 2 | 2022 | 64 | 0.200 |
Why?
|
| Overweight | 3 | 2024 | 263 | 0.200 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 129 | 0.200 |
Why?
|
| Quality of Life | 2 | 2020 | 976 | 0.200 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 16 | 0.200 |
Why?
|
| Infant | 4 | 2016 | 1083 | 0.200 |
Why?
|
| Health Personnel | 1 | 2024 | 131 | 0.200 |
Why?
|
| Socioeconomic Factors | 3 | 2023 | 436 | 0.200 |
Why?
|
| Obesity | 5 | 2024 | 1179 | 0.190 |
Why?
|
| Models, Statistical | 1 | 2023 | 180 | 0.190 |
Why?
|
| Hallucinogens | 1 | 2022 | 12 | 0.190 |
Why?
|
| Adolescent | 8 | 2024 | 3643 | 0.190 |
Why?
|
| Medication Adherence | 1 | 2024 | 160 | 0.190 |
Why?
|
| Periodontitis | 1 | 2022 | 9 | 0.180 |
Why?
|
| Cohort Studies | 6 | 2022 | 1852 | 0.180 |
Why?
|
| Adiposity | 1 | 2023 | 199 | 0.180 |
Why?
|
| Restless Legs Syndrome | 1 | 2021 | 2 | 0.180 |
Why?
|
| Parent-Child Relations | 1 | 2022 | 43 | 0.180 |
Why?
|
| Pilot Projects | 5 | 2023 | 566 | 0.180 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 54 | 0.170 |
Why?
|
| Telemedicine | 1 | 2023 | 117 | 0.170 |
Why?
|
| Antigens, Differentiation | 1 | 2021 | 25 | 0.170 |
Why?
|
| Primary Health Care | 3 | 2022 | 231 | 0.170 |
Why?
|
| Conversion Disorder | 1 | 2020 | 2 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2024 | 2338 | 0.170 |
Why?
|
| Psychophysiologic Disorders | 1 | 2020 | 5 | 0.160 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 89 | 0.160 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 77 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 32 | 0.160 |
Why?
|
| Stress, Psychological | 2 | 2021 | 226 | 0.150 |
Why?
|
| Health Services Research | 1 | 2019 | 81 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2019 | 19 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 37 | 0.150 |
Why?
|
| Parathyroid Hormone | 1 | 2018 | 47 | 0.140 |
Why?
|
| SEER Program | 1 | 2018 | 33 | 0.140 |
Why?
|
| Minority Groups | 1 | 2018 | 87 | 0.140 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 43 | 0.140 |
Why?
|
| Nicotinic Agonists | 1 | 2018 | 40 | 0.140 |
Why?
|
| Living Donors | 1 | 2018 | 64 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 121 | 0.140 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 23 | 0.140 |
Why?
|
| Weight Loss | 1 | 2021 | 462 | 0.130 |
Why?
|
| Diet | 1 | 2020 | 393 | 0.130 |
Why?
|
| Mothers | 2 | 2022 | 91 | 0.130 |
Why?
|
| Food Preferences | 1 | 2017 | 35 | 0.130 |
Why?
|
| Viral Load | 3 | 2023 | 73 | 0.130 |
Why?
|
| Vitamin D | 1 | 2018 | 189 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 215 | 0.130 |
Why?
|
| Age Factors | 2 | 2017 | 1202 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 471 | 0.130 |
Why?
|
| Medicare | 1 | 2018 | 213 | 0.130 |
Why?
|
| Transportation of Patients | 1 | 2017 | 26 | 0.130 |
Why?
|
| Homosexuality, Male | 3 | 2022 | 105 | 0.120 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 25 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 43 | 0.120 |
Why?
|
| Comorbidity | 4 | 2021 | 573 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2015 | 205 | 0.120 |
Why?
|
| Sports | 1 | 2017 | 41 | 0.120 |
Why?
|
| Ohio | 1 | 2016 | 64 | 0.120 |
Why?
|
| Nicotine | 1 | 2018 | 177 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2016 | 14 | 0.120 |
Why?
|
| Hospitals, Rural | 1 | 2016 | 12 | 0.120 |
Why?
|
| Triage | 1 | 2016 | 75 | 0.120 |
Why?
|
| Sex Factors | 1 | 2017 | 684 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 72 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 412 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 58 | 0.110 |
Why?
|
| Binomial Distribution | 1 | 2015 | 2 | 0.110 |
Why?
|
| Likelihood Functions | 1 | 2015 | 48 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 78 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2016 | 369 | 0.110 |
Why?
|
| Feasibility Studies | 3 | 2023 | 308 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 64 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 98 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2015 | 146 | 0.110 |
Why?
|
| Echocardiography | 1 | 2015 | 191 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 183 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2016 | 172 | 0.110 |
Why?
|
| Sarcolemma | 1 | 2014 | 4 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 172 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 21 | 0.110 |
Why?
|
| Mitochondria, Heart | 1 | 2014 | 18 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 512 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2016 | 162 | 0.110 |
Why?
|
| Malawi | 1 | 2013 | 22 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 245 | 0.100 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 20 | 0.100 |
Why?
|
| Stroke | 1 | 2019 | 610 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2017 | 867 | 0.100 |
Why?
|
| Vagina | 2 | 2024 | 59 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 499 | 0.100 |
Why?
|
| Peptide Nucleic Acids | 1 | 2012 | 3 | 0.100 |
Why?
|
| Candida | 1 | 2012 | 7 | 0.100 |
Why?
|
| Candidiasis | 1 | 2012 | 6 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 42 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2012 | 41 | 0.090 |
Why?
|
| Heterosexuality | 2 | 2022 | 15 | 0.090 |
Why?
|
| Milk, Human | 1 | 2011 | 17 | 0.090 |
Why?
|
| Causality | 2 | 2021 | 39 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2021 | 94 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 1015 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1581 | 0.080 |
Why?
|
| Universities | 2 | 2023 | 153 | 0.080 |
Why?
|
| Mass Screening | 2 | 2023 | 268 | 0.080 |
Why?
|
| Students | 2 | 2023 | 179 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 543 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2024 | 909 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 780 | 0.070 |
Why?
|
| Pregnancy | 2 | 2024 | 981 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2287 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3460 | 0.060 |
Why?
|
| Animals | 2 | 2015 | 7599 | 0.060 |
Why?
|
| Registries | 2 | 2018 | 320 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 783 | 0.060 |
Why?
|
| Dominican Republic | 1 | 2024 | 2 | 0.050 |
Why?
|
| Uganda | 1 | 2024 | 8 | 0.050 |
Why?
|
| Fertilization | 1 | 2024 | 5 | 0.050 |
Why?
|
| Gardnerella | 1 | 2024 | 1 | 0.050 |
Why?
|
| Microbial Interactions | 1 | 2024 | 1 | 0.050 |
Why?
|
| Prevotella | 1 | 2024 | 8 | 0.050 |
Why?
|
| Poisson Distribution | 1 | 2023 | 16 | 0.050 |
Why?
|
| Cameroon | 1 | 2023 | 4 | 0.050 |
Why?
|
| Weight Gain | 1 | 2024 | 112 | 0.050 |
Why?
|
| Child | 2 | 2022 | 2478 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 183 | 0.050 |
Why?
|
| Testosterone | 1 | 2023 | 48 | 0.050 |
Why?
|
| Stavudine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Ritonavir | 1 | 2022 | 3 | 0.050 |
Why?
|
| Alkynes | 1 | 2022 | 2 | 0.050 |
Why?
|
| Integrase Inhibitors | 1 | 2022 | 1 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2022 | 21 | 0.050 |
Why?
|
| Schools | 1 | 2023 | 67 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 83 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2022 | 19 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 67 | 0.050 |
Why?
|
| Social Support | 1 | 2023 | 183 | 0.050 |
Why?
|
| Length of Stay | 2 | 2014 | 329 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2022 | 36 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 21 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 20 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 20 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 188 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 67 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 230 | 0.040 |
Why?
|
| Motor Activity | 1 | 2023 | 327 | 0.040 |
Why?
|
| Sleep Deprivation | 1 | 2020 | 10 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 125 | 0.040 |
Why?
|
| Internal-External Control | 1 | 2020 | 17 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 445 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2021 | 103 | 0.040 |
Why?
|
| Parents | 1 | 2022 | 148 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2020 | 26 | 0.040 |
Why?
|
| Safety | 1 | 2020 | 77 | 0.040 |
Why?
|
| Attention | 1 | 2020 | 82 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2020 | 35 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 71 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 44 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 2195 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 355 | 0.040 |
Why?
|
| Walking | 1 | 2020 | 212 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 880 | 0.040 |
Why?
|
| Selection Bias | 1 | 2019 | 13 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2020 | 133 | 0.040 |
Why?
|
| Minority Health | 1 | 2018 | 9 | 0.040 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 39 | 0.040 |
Why?
|
| HIV | 1 | 2018 | 25 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 29 | 0.040 |
Why?
|
| Carbon Monoxide | 1 | 2018 | 9 | 0.040 |
Why?
|
| Accidents, Traffic | 1 | 2020 | 197 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 517 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2018 | 94 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 467 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 134 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 91 | 0.030 |
Why?
|
| Personal Autonomy | 1 | 2017 | 9 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 682 | 0.030 |
Why?
|
| Bone Density | 1 | 2018 | 203 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 95 | 0.030 |
Why?
|
| Observation | 1 | 2016 | 24 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 403 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2015 | 34 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 138 | 0.030 |
Why?
|
| Health Behavior | 1 | 2017 | 234 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 148 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 98 | 0.030 |
Why?
|
| Diastole | 1 | 2015 | 98 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 356 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 360 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 316 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 205 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 186 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2014 | 22 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 185 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 894 | 0.030 |
Why?
|
| Body Height | 1 | 2014 | 33 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2014 | 111 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2016 | 495 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 1282 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2015 | 421 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 821 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 194 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 105 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 2529 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1547 | 0.020 |
Why?
|